Pox­el takes write­down on NASH drug as it con­tin­ues lay­offs, search for cash

France’s Pox­el still be­lieves that it can blaze a path for­ward in rare dis­eases — but be­fore it can con­vince in­vestors or part­ners of that, it’s con­tin­u­ing to tight­en the purse strings.

The com­pa­ny is tak­ing a $17.6 mil­lion (€16.6 mil­lion) im­pair­ment on its lead pro­gram, PXL065, re­flect­ing a di­min­ished val­ue for the drug when “tak­ing in­to ac­count the com­pa­ny’s need to ob­tain ad­di­tion­al fi­nanc­ing to pur­sue its de­vel­op­ment plan in NASH or ALD, its cur­rent mar­ket cap­i­tal­iza­tion and the macro­eco­nom­ic con­text in which it op­er­ates.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER